The evolution of sex chromosomes has resulted in numerous species in which females inherit two X chromosomes but males have a single X, thus requiring dosage compensation. MSL (Male-specific lethal) complex increases transcription on the single X chromosome of Drosophila males to equalize expression of X-linked genes between the sexes 1 . The biochemical mechanisms used for dosage compensation must function over a wide dynamic range of transcription levels and differential expression patterns. It has been proposed 2 that the MSL complex regulates transcriptional elongation to control dosage compensation, a model subsequently supported by mapping of the MSL complex and MSL-dependent histone 4 lysine 16 acetylation to the bodies of X-linked genes in males, with a bias towards 39 ends 3-7 . However, experimental analysis of MSL function at the mechanistic level has been challenging owing to the small magnitude of the chromosome-wide effect and the lack of an in vitro system for biochemical analysis. Here we use global run-on sequencing (GRO-seq) 8 to examine the specific effect of the MSL complex on RNA Polymerase II (RNAP II) on a genome-wide level. Results indicate that the MSL complex enhances transcription by facilitating the progression of RNAP II across the bodies of active X-linked genes. Improving transcriptional output downstream of typical gene-specific controls may explain how dosage compensation can be imposed on the diverse set of genes along an entire chromosome.
The evolution of sex chromosomes has resulted in numerous species in which females inherit two X chromosomes but males have a single X, thus requiring dosage compensation. MSL (Male-specific lethal) complex increases transcription on the single X chromosome of Drosophila males to equalize expression of X-linked genes between the sexes 1 . The biochemical mechanisms used for dosage compensation must function over a wide dynamic range of transcription levels and differential expression patterns. It has been proposed 2 that the MSL complex regulates transcriptional elongation to control dosage compensation, a model subsequently supported by mapping of the MSL complex and MSL-dependent histone 4 lysine 16 acetylation to the bodies of X-linked genes in males, with a bias towards 39 ends [3] [4] [5] [6] [7] . However, experimental analysis of MSL function at the mechanistic level has been challenging owing to the small magnitude of the chromosome-wide effect and the lack of an in vitro system for biochemical analysis. Here we use global run-on sequencing (GRO-seq) 8 to examine the specific effect of the MSL complex on RNA Polymerase II (RNAP II) on a genome-wide level. Results indicate that the MSL complex enhances transcription by facilitating the progression of RNAP II across the bodies of active X-linked genes. Improving transcriptional output downstream of typical gene-specific controls may explain how dosage compensation can be imposed on the diverse set of genes along an entire chromosome.
To investigate how the MSL complex specifically increases transcription of X-linked genes, we performed GRO-seq in SL2 cells, a male Drosophila cell line that has been extensively characterized for MSL function 4, 9 . To show the average enrichment across genes, a 3-kb 'metagene' profile was plotted in which the internal regions were rescaled so that all genes appear to have the same length ( Fig. 1 ). Analysis was restricted to expressed genes that were sufficiently large (.2.5 kb) so that gene-body effects could be clearly assessed (822 X-linked genes, 3,420 autosomal genes), and all gene profiles were normalized by their copy number as determined by analysis of SL2 DNA content 10 . High correlation coefficients were observed between replicate libraries (Pearson correlation coefficient, $ 0.98; Supplementary Fig. 1 ). The metagene profiles revealed a prominent 59 peak of paused RNAP II consistent with previous chromatin immunoprecipitation (ChIP) and analysis of short 59 RNAs 11, 12 (RNA-seq). In addition, a peak of RNAP II density downstream of the metagene 39 processing site is evident, possibly due to slow release in regions of transcription termination 8 . The 39 peak is present even when the influence of neighbouring gene transcription is eliminated ( Supplementary  Fig. 2 ).
The central question with regard to dosage compensation is how genes on the X chromosome differ on average from genes on autosomes. Overall, we found that RNAP II density on active X-linked genes was higher than on autosomal genes, specifically over gene bodies (Fig. 1a ). The increase in tag density over the bodies of X-linked genes compared to autosomal genes was approximately 1.4-fold, consistent with previous estimates of MSL-dependent dosage compensation 9, 10, 13 . We also performed RNAP II ChIP in SL2 cells, confirming higher occupancy on X-linked genes compared to autosomes but with lower resolution and reduced sensitivity (Supplementary Fig. 3 ). Therefore, we proceeded with GRO-seq to analyse X and autosomal differences.
To measure how X and autosomes differed on average in the distribution of elongating RNAP II, we segmented genes into their 59 500 bp and the remainder of the coding region. We subdivided further the remainder of the coding region into 59 and 39 segments (25% and 75%, respectively). Using this segmentation, we quantified RNAP II pausing and elongation separately on the basis of the unscaled GROseq signal (Fig. 1b ). The pausing index (PI) was previously defined as the ratio of the GRO-seq signal at the 59 peak to the average signal over gene bodies 8 . Here, we calculated the PI for X and autosomal genes as the ratio of the 59 peak (segment A) to the first 25% of the remaining gene body (segment B), and found no statistically significant difference when the two groups were compared ( Fig. 1b ).
To examine separately transcription elongation across gene bodies, we defined the elongation density index (EdI) as the ratio of tag density in the 39 region of each gene (segment C) compared to its 59 region after the first 500 bp (segment B). In contrast to our analysis of 59 pausing, we found statistically significant differences in EdI (P value , 0.0162) between X and autosomes ( Fig. 1b ). This conclusion was robust to how the 59 and 39 regions of genes were divided (Supplementary Table 1 ). As defined, the average PI (log scale) is a positive number because RNAP II is generally enriched at 59 ends compared to gene bodies; the average EdI (log scale) is a negative number, as the relative density of RNAP II typically decreases from the beginning to the end of gene bodies. We conclude that X-linked genes, on average, show a significantly smaller decrease in RNAP II density along their gene bodies when compared to autosomal genes.
To measure the specific contribution of the MSL complex to the increase in RNAP II within X-linked gene bodies, we used MSL2 RNA interference (RNAi) to reduce complex levels in male SL2 cells as described previously 9 . Excellent correlations between replicate data sets were observed ( Supplementary Fig. 1 ). To confirm the X-specific effect of MSL2 RNAi, we computed the distributions of the GRO-seq signal (averaged over the bodies of genes excluding the 59 peak) for all genes before and after RNAi. When comparing X versus autosomes, we found a preferential decrease on the X chromosome, with an average control:MSL RNAi ratio of 1.4 ( Fig. 2a ). MSL-dependent changes in average GRO-seq density showed a weak but statistically significant correlation with changes in steady-state messenger RNA levels assayed by expression array 9 (Pearson correlation 5 0.22, P value , 1 3 10 215 ) or mRNA-Seq 10 (Pearson correlation 5 0.30, P value , 1 3 10 215 ). These results confirm that MSL-dependent changes in steadystate RNA levels reflect differences in active transcription on the X chromosome.
In addition to assessing the average decrease of X-linked RNAP II density after MSL2 RNAi, we asked whether any genes showed strong MSL-dependence, a hallmark of the roX genes that encode RNA components of the complex 14, 15 . We found that roX2 showed a strong loss in GRO-seq density (ninefold) after MSL2 RNAi, as predicted ( Fig. 2b and Supplementary Fig. 4 ). Interestingly, in the untreated or control RNAi samples, there is a prominent GRO-seq peak downstream of the major roX2 39 end, coincident with an MSL recruitment site (see discussion later). roX1 expression is low in this isolate of SL2 cells, and no other expressed genes on X or autosomes showed strong MSL dependence in our assays (.6-fold). Examples of additional individual gene profiles are shown in Supplementary Figs 5 and 6.
Next we compared the average RNAP II density along X and autosomal metagene profiles after control and MSL2 RNAi. Unlike our initial analysis of X and autosomes, where different gene populations were compared ( Fig. 1 ), here we could examine the same genes in the presence and absence of the MSL complex ( Fig. 3 ). We found that after MSL2 RNAi, the density of elongating RNAP II over the bodies of X-linked genes decreased, approaching the level on autosomes ( Fig. 3 and Supplementary Fig. 7) . The presence of the MSL complex affected RNAP II density starting just downstream of the 59 peak and continuing through the bodies of X-linked genes ( Fig. 3 and Supplementary  Fig. 7 ). Thus, GRO-seq functional data correlate with physical association of the MSL complex, which is biased towards the 39 ends of active genes on the male X chromosome 4,5 .
To quantify the differences in density of engaged RNAP II in the presence and absence of the MSL complex, we calculated the PI and EdI for each gene, followed by the PI and EdI ratios comparing MSL2 and control RNAi treatment. We found that both X and autosomes increased PI and decreased EdI after MSL2 RNAi treatment ( Supplementary Fig. 8 ). However, in each case the change was larger on X than on autosomes, and the most profound difference was an MSL-dependent change in EdI on X compared with autosomes (P , 1 3 10 215 ; Fig. 3b ). EdI was computed, as before, by defining the 59 and 39 regions as 25% and 75%, respectively, of the gene body after removing the 59 peak, but the difference was statistically significant for all other values until the 39 end was reached ( Supplementary  Table 1 ). When these analyses were performed separately for two independently prepared sets of GRO-seq libraries ( Supplementary  Fig. 9 ), the results were also statistically significant (P value , 7.6 3 10 214 , P value , 1.1 3 10 24 for each of two replicates). We conclude that the MSL complex causes the transcriptional elongation profiles of X-linked genes to differ from those of autosomal genes.
To visualize the location along gene bodies at which the MSL complex functions, we calculated control:MSL2 RNAi GRO-seq ratios and generated a metagene profile (Fig. 4a ). Here, values above zero represent higher relative amounts of engaged RNAP II in the presence of the MSL complex compared to after RNAi treatment. In contrast, values below Here, the distributions of these ratios are plotted for all genes on X and autosomes. b, GRO-seq sense-strand read densities within the roX2 gene (xaxis denotes base pairs from the roX2 transcription start site) for the untreated, control RNAi and MSL2 RNAi samples. Schematic below GRO-seq profiles indicates the location of the DHS site, which contains sequences that can recruit the MSL complex to the X chromosome.
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zero represent a relative increase in engaged RNAP II after MSL2 RNAi.
In the absence of the MSL complex, there is a relative increase in the amount of RNAP II localized to the 59 ends of both autosomal and X-linked genes, perhaps due to relocalization of RNAP II from the bodies of X-linked genes (Fig. 4a ). A limitation of the GRO-seq assay is that we cannot currently distinguish between initiating and 59 paused polymerase, so we cannot assign a definitive role for this 59 increase in RNAP II after MSL2 RNAi treatment. However, relative RNAP II levels over autosomal gene bodies do not increase, indicating that any relocalized enzyme in this experiment is likely to remain paused rather than progressing across transcription units. This is consistent with a model in which the functional outcome of MSL2 RNAi is to shift RNAP II density away from productive transcription through X-linked gene bodies.
We plotted the local effect of the MSL complex in Fig. 4a to compare it to the status of histone 4 lysine 16 (H4K16) acetylation (Fig. 4b ) catalysed by the MOF component of the MSL complex 3, 16 . H4K16 acetylation typically is enriched at the 59 ends of most active genes in mammals and flies 6, 17 ; in contrast, a 39 bias of this mark is a distinctive characteristic of the dosage compensated male X chromosome in Drosophila 3,6,7 . Interestingly, there is an overall coincidence across gene bodies between the MSL-complex-dependent GRO-seq signal and the presence of H4K16 acetylation 7 (Fig. 4a ). How might H4K16 acetylation biased towards the 39 end of genes generate the improved transcriptional elongation indicated by our GRO-seq results? During transcription elongation, nucleosomes are thought to comprise a barrier to the progress of RNAP II [18] [19] [20] and several well-studied elongation factors, including Spt6 and the FACT complex, are proposed to function by removing nucleosomes that block RNAP II progression and replacing them in the wake of transcription 18, 21 . Interestingly, H4K16 acetylation of nucleosomes has been observed to act in opposition to the formation of higher-order chromatin structure in vitro 22, 23 . Thus, H4K16 acetylation is likely to reduce further the steric hindrance to RNAP II progression through chromatin. Improving the entry of RNAP II into the bodies of genes may allow 59, gene-specific events to proceed at an increased but still regulated rate. Furthermore, reduction in the repressive effect of nucleosomes could increase mRNA output by improving the processivity of RNAP II on each template. Available methodologies cannot distinguish between these mechanisms in vivo, and therefore future approaches will be required to assess their relative contributions to dosage compensation.
In addition to increasing the transcription of X-linked genes for dosage compensation, the MSL complex also positively regulates the roX noncoding RNA components of the complex, to promote their male specificity 14, 15 . roX1 expression is low in our SL2 cell line, but our GRO-seq data indicate that active transcription of roX2 is highly dependent on MSL2 as predicted ( Fig. 2b and Supplementary Fig.  4 ). Interestingly, there is a strong GRO-seq peak at the 39 roX2 DHS (DNaseI hypersensitive site), which contains sequences important for b, Ratios of PI between control and MSL2 RNAi treated cells are not significantly different for genes on the X chromosome (red bar) compared to those on autosomes (blue bar). In contrast, ratios of EdI between the control and MSL2 RNAi sample decreased significantly for genes on the X (red bar) compared to those on the autosomes (blue bar). PI and EdI were calculated as described for Fig. 1 . Error bars represent a 95% confidence interval for the mean PI or EdI ratios (1.96 3 s.e.m.: n 5 1,358 (X genes); n 5 6,135 (autosomal genes)).
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targeting the MSL complex to the X chromosome. Sites of roX gene transcription are thought to be critical for MSL complex assembly 24, 25 . Therefore, it is possible that paused RNAP II at the roX2 DHS could promote an open chromatin structure that facilitates MSL complex targeting or incorporation of noncoding roX2 RNA into the complex. In summary, we propose that the MSL complex functions on the male X chromosome to promote progression and processivity of RNAP II through the nucleosomal template, as foreseen by Lucchesi 2 . Improving transcriptional output downstream of typical gene-specific regulation makes biological sense when compensating the diverse set of genes found along an entire chromosome.
METHODS SUMMARY
To measure the density of engaged RNAP II, GRO-Seq experiments were conducted on DRSC SL2 cells grown in Schneider's medium with 10% FBS 8 . To determine how the MSL complex contributes to dosage compensation, MSL2 and control (GFP) RNAi treatments were conducted using a bathing protocol 9 . Nuclei were subjected to GRO-seq analysis after RNAi treatment. Two biological replicates were performed for the untreated, control RNAi and MSL2 RNAi experiments.
METHODS
RNAi and cell culture methods. Control and MSL2 RNAi were performed in SL2-DRSC cells as described previously 7 . The control RNAi construct targeted the eGFP gene that is not present in SL2 cells, and the experimental RNAi construct targeted the MSL2 gene (http://www.flyrnai.org: DRSC 00829). Primer sequences for generation of the eGFP double-stranded RNA (dsRNA) template by PCR from pEGFP-N1(Clontech) were: forward, 59-TAATACGACTCACTATAGGGAGA GGTGAGCA-AGGGCGA-GGAGCT-39; and reverse, 59-TAATACGACTCACT ATAGGGAGATCT-TGAAGTTCACCTTGATGC-CG-39. The primers used for amplifying the MSL2 gene from Drosophila genomic DNA were: 59-TAA TACGACTCACTATAGGGAGAGTTGGCTGTG-CTGGCTG-39; and reverse, 59-TAATACGACTCACTATAGGGAGATGTTGGCTCGTCAC-TGTC-39.
dsRNA was synthesized from PCR products containing T7 promoters using the Ambion MEGAscript kit, and 225 mg of dsRNA was added to 2 3 10 7 cells in a T225 flask. RNAi treatment was performed for 6 days after which mRNA was prepared and transcriptionally active nuclear extracts were generated as described later. mRNA preparation, complementary DNA synthesis and qPCR analysis of roX2 and msl2 RNA compared with the PKA normalization control were performed as described previously 7 . A 12.3-fold average decrease of msl2 mRNA was observed after MSL2 RNAi treatment when compared with the control treatment. Preparation of GRO-seq libraries for next-generation sequencing. Preparation of transcriptionally active nuclei from Drosophila SL2-DRSC cells after RNAi treatment was conducted as follows: SL2 cells grown in a T225 tissue culture flask were scraped and 1 3 10 8 cells were pelleted at 500g for 3 min at 4 uC. Then, cells were washed in 10 ml of cold PBS and spun at 500g for 3 min at 4 uC. Cells were swelled by resuspending gently in 10 ml ice-cold swelling buffer (10 mM Tris (pH 5 7.5), 2 mM MgCl 2 , 3 mM CaCl 2 ) and placed on ice for 5 min. Next, cells were pelleted at 600g for 10 min at 4 uC. Pelleted cells were resuspended in 1 ml lysis buffer (10 mM Tris (pH 5 7.5), 2 mM MgCl 2 , 3 mM CaCl 2 , 10% glycerol, 0.5% NP40, 2 U ml 21 SUPERaseIN (Invitrogen)) and pipetted 20 times with a P1000 tip with the end cut off. Nine millilitres of lysis buffer was added and nuclei were pelleted at 600g for 5 min. Nuclei were washed in 1 ml lysis buffer and then 9 ml was added followed by pelleting for 5 min at 600g at 4 uC. A small aliquot was taken for Trypan blue staining to check that lysis occurred and nuclei were still intact. Next, nuclei were resuspended in 1 ml freezing buffer (50 mM Tris-Cl (pH 5 8.3), 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA) using a P1000 tip with the end cut off. Nuclei were pelleted for 1 min and resuspended in 500 ml of freezing buffer and aliquoted into 100 ml aliquots and frozen in liquid nitrogen. All solutions were prepared with DEPC-treated water.
GRO-seq libraries were prepared as described previously 8 with the following changes: glycoblue (3 ml: 15 mg ml 21 ; Ambion) was used in all of the ethanol precipitations to assure the release of the nascent RNAs from the interior surface of Eppendorf tubes; and wash buffers for BrU immunoprecipitation differ from those described in ref. 8 as follows. Firstly, high salt wash buffer for anti-BrdU (0.253 SSPE, 1 mM EDTA, 0.05% Tween, 137.5 mM NaCl; secondly, binding buffer for anti-BrdU (0.253 SSPE, 1 mM EDTA, 0.05% Tween, 37.5 mM NaCl); thirdly, elution buffer (20 mM DTT, 300 mM NaCl, 50 mM Tris-Cl pH 7.5, 1 mM EDTA, 0.1% SDS); lastly, all immunoprecipitation wash buffers contain superRNAsin (1 ml per 5 ml buffer) (Invitrogen) to block degradation that can occur during the immunoprecipitation process.
Overview of computational analysis of GRO-seq data. For data generation and quality assessment, sequencing was performed on an Illumina Genome Analyser IIx. Two independent biological replicates were generated for each of the three experiments (untreated, control RNAi and MSL2 RNAi). Data are available from GEO under accession numbers GSE25321 and GSE25887. Reads were aligned to the D. melanogaster genome (dm3) using the Bowtie alignment software 26 . Only uniquely mapping reads with no more than one mismatch were retained. We obtained 10.6 million aligned reads from the untreated samples To assess the agreement between replicates, a correlation coefficient was computed between sense-strand read densities across genes in the two replicates for each of the three treatments. The agreement between replicates is excellent, with the following correlation coefficients: (1) untreated: Spearman, 0.97; Pearson, 0.98;
(2) control RNAi: Spearman, 0.99; Pearson, 0.98; and (3) MSL2 RNAi: Spearman, 0.99; Pearson, 0.98 ( Supplementary Fig. 1 ). For most of the analysis, the two replicates were combined and processed together to increase statistical power. Key results were also confirmed in each replicate separately. Generating average profiles. To examine the difference between RNAi and control as well as between X and autosomes, it was important to derive accurate 'metagene' profiles. To improve existing TSS annotations, previously published small (,100 bp), capped nuclear RNA-seq data 27 were used. This data set contains RNA isolated from 59 ends of transcripts. Starting with FlyBase build 5.23, start sites for each annotated transcript were adjusted by up to 150 bp from the original location. The position within the 301 bp window centred on the existing TSS annotation with the highest number of reads from this capped nuclear RNAseq data set was annotated as the new TSS for that transcript. In the event that two positions within the search space had the same number of reads, the most 59 position was designated the TSS. Finally, transcripts with identical start sites were filtered out, ensuring each annotation is unique.
To derive the metagene profile, we first computed the profile for each gene before computing the average. For each gene, the GRO-seq read profile on each strand was normalized to total sequencing depth and was smoothed using Gaussian smoothing with a bandwidth of 200 bp. To adjust for copy number variations, alignability and sequencing biases, the GRO-seq read density was further normalized by the analogous density of genomic sequencing reads 10 . Specifically, each gene was divided into 200 bins and the log ratio (base 2) between GRO-seq and genomic sequencing read densities were computed for each bin. To avoid ratios becoming infinity when the denominator is zero, we applied the common technique of adding a pseudocount (1 in this case) to both numerator and denominator. To average the log ratios across genes for the metagene profile, the 59 end (1 kb upstream of the TSS to 500 bp downstream) and the 39 end (500 bp upstream of the transcript termination site (TTS) to 1 kb downstream) were unscaled. The region within the gene body extending from 500 bp downstream of the TSS and 500 bp upstream of the TTS was scaled to 2 kb (see Fig. 1a ).
Only genes longer than 2.5 kb were considered to avoid short genes in which the 59 peak is difficult to distinguish from the body of the gene. In addition, genes with less than one RPKM (reads per kilobase per million)/gene copy in the untreated GRO-seq sample were considered unexpressed and thus excluded. In a number of genes, the read distribution downstream of the 59 peak contained high peaks, possibly due to unannotated internal TSS that distorted the average profiles. To mitigate the effect of these outliers, we removed 5% of the genes in which the highest density peak was downstream of the first 500 bp. These genes were not removed when computing P values or for other analyses.
The ChIP-chip metagene profiles ( Supplementary Fig. 3) were computed from array data by the same scaling method used for the GRO-seq metagene profiles. There was no need for further normalization in these profiles because we also normalized to array input, thereby controlling for copy number.
Individual gene profiles ( Fig. 2b and Supplementary Figs 4-6) were computed in a similar manner to the metagene profiles, only no scaling was performed and a 100-bp sliding window was used to smooth the reads instead of Gaussian smoothing. As before, read density was normalized to total sequencing depth and for copy number using genomic sequencing reads as in the GRO-seq metagene profile calculations.
The control/MSL2 RNAi log ratio metagene plot ( Fig. 4a ) was produced by taking the log ratio of the Gaussian-smoothed read densities in MSL2 RNAi and control samples across the body of each gene. The log ratios (base 2) were computed for each gene before scaling (with pseudocount of 1) and then averaged across genes (thus, this ratio is not simply the ratio of the profiles in Fig. 3a) . Overall, higher values in Fig. 4a represent a greater drop in the GRO-seq signal after MSL2 RNAi treatment.
Computing the PI and EdI. To compare the level of RNAP II at the 59 ends of genes compared with that progressing into gene bodies, we defined a 'pausing index' (PI) as the ratio of 59 GRO-seq read density within the first 500 bp downstream of the TSS to the read density within the next 25% of the gene body. The 59 read density is calculated as the number of sense-strand reads in the 59 region divided by the number of uniquely mappable positions (as determined using PeakSeq 28 ) in this same region. A position is 'mappable' if, given only the 36 bp sequence at that position, the position in the genome can be uniquely identified. Correcting for mappability in this manner prevents regions that have no reads because they are unmappable from biasing the analysis. A similar calculation is performed to determine the density in the next 25% of the gene. A high PI indicates that RNAP II is biased towards the 59 end.
To analyse the distribution of active RNAP II within a given gene, we calculated an 'elongation density index' (EdI) by taking the ratio of the 39 read density to the 59 read density. The first 500 bp of the gene is excluded from this calculation to eliminate the effect of the large 59 peak frequently associated with paused polymerase. The remainder of the gene is then split into two portions, the 59 region and the 39 region. We state the main results with the 59 region containing the first 25% of the gene (after the first 500 bp) and the 39 region the remaining 75%, but multiple points of division were tested (Supplementary Table 1 ). The 39 density is calculated as it was done above. A low EdI indicates that RNAP II is biased towards the 59 end, whereas a larger value indicates greater RNAP II towards the 39 end.
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